Podcasts about Head and neck cancer

While the first goal of head and neck cancer surgery is always clear margins, a secondary goal is reconstruction, whether for functionality of cosmetic improvement. Wesley McIlwain, MD, a head and neck cancer surgeon at Sarasota Memorial discusses options for reconstruction and how the team at the Brian D. Jellison Cancer Institute comes together to get patients the best outcomes.You can also watch the video recording on our Vimeo channel here.For more health tips & news you can use from experts you trust, sign up for Sarasota Memorial's monthly digital newsletter, Healthe-Matters.

Human Papillomavirus, or HPV, is a virus that infects the skin and wet surfaces of the body. It's a disease that's commonly spread through sexual activity, and over 80% of people will get it at some point in their lifetime. HPV is an endemic disease, which, in epidemiology, means that it is constantly present in a particular population. While most people recover from HPV, there can be complications. It is responsible for more than 90% of anal and cervical cancers and can also cause oropharyngeal cancer. Dr. Wu, a board-certified otolaryngologist, specializes in head and neck surgical oncology. Diseases like HPV and cancers that affect the head and neck are what she sees most in her patients. Working closely with other multispecialty experts at PNI, Dr. Wu is committed to guiding her patients through their cancer journeys. Listen in.

Host: Mindy McCulley, MS Family and Consumer Sciences Extension Specialist for Instructional Support, University of Kentucky  Guest: Dr. Melina Windon, MD,  Assistant Professor of Otolaryngology, UK Markey Cancer Center Cancer Conversations Episode 63 In this episode of Cancer Conversations on Talking FACS, Dr. Melina Windon, an Assistant Professor of Ear, Nose and Throat Surgery at the University of Kentucky Markey Cancer Center, discusses head and neck cancers. Dr. Windon provides insights into her specialty, emphasizing the critical aspects of cancer diagnosis, treatment, and reconstructive surgery, which restores patients' ability to speak and swallow. Listeners will gain valuable knowledge about the primary risk factors for head and neck cancer, including tobacco use, HPV exposure, and heavy alcohol consumption. Dr. Windon highlights the importance of the HPV vaccine as a preventive measure, particularly targeting both boys and girls at a young age. She also explains the significance of routine oral cancer screenings and early detection of symptoms like persistent spots or lumps in the mouth or neck. The episode underscores the higher incidence and mortality rates of head and neck cancer in Kentucky, stressing the urgency for awareness and timely medical intervention. Tune in to learn more about preventing and managing these formidable cancers and the role of groundbreaking reconstructive surgery in restoring quality of life for affected individuals. Connect with the UK Markey Center Online Markey Cancer Center On Facebook @UKMarkey On X @UKMarkey

In this episode of I Saved You. Now, Do the Dishes., I pull back the curtain on the chaotic world of cancer treatment scheduling and pain management. Spoiler: it's less “organized care plan” and more “full-time logistical nightmare.” From juggling 12 appointments in a week to coordinating three different pharmacy pick-ups (yes, really) for five different drugs, I talk about what it's like to be the caregiver, the calendar, and the human pharmacy technician—all while trying to make sure my husband isn't suffering in silence. If you've ever felt like managing care takes more energy than the illness itself, this one's for you. You're not alone. And yes, it's okay to have someone else do the damn dishes.

April 14-18 is Head and Neck Cancer Awareness Week and Dr. Kademani, president and founder of the Head and Neck Cancer Foundation,

April 14-18 is Head and Neck Cancer Awareness Week and Dr. Kademani, president and founder of the Head and Neck Cancer Foundation,

Join us as we dive into the complexities of head and neck cancer, the various types that exist, and the symptomatic signs you should watch out for. Afton Swanson from Riverside Cancer Institute will guide us through this critical health topic, shedding light on both the medical and emotional journey faced by patients.

Southern Remedy Healthy and Fit is hosted by Josie Bidwell, Professor of Preventive Medicine and Nurse Practitioner at UMMC. If you have a question for Josie, you can email fit@mpbonline.org. It this episode, Josie talks about detection and prevention of head and neck cancer with Physician's Assistant Lindsey McAlpin and Nurse Practitioner Sharon Vickers, but from the UMMC Department of Otolaryngology. Hosted on Acast. See acast.com/privacy for more information.

Dr. Sue Yom, Editor in Chief, co-hosts with Dr. Lachlan McDowell, Consultant Radiation Oncologist at the Princess Alexandra Hospital in Queensland, Australia and our journal's Head and Neck Cancer Section Editor. Guests are Dr. Sean McBride, Radiation Oncologist at Memorial Sloan Kettering Cancer Center and Chief of External Beam Radiotherapy at the Manhattan site, who authored an editorial, Oligometastatic HNSCC: Is SABR the Solution?, and Dr. Juliette Thariat, Professor in Radiation Oncology at Cancer Center Baclesse in Normandy, France, Secrétaire Nationale at the GORTEC, and first author of our featured article, Survival Without Quality of Life Deterioration in the GORTEC 2014-04 "OMET" Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR.

Advanced Reconstructive Surgery for Head and Neck Cancer with guest Dr. Saral Mehra March 9, 2025 Yale Cancer Center visit: https://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

In this episode during the month of January, we discuss this Transformational moment in history that we are all experiencing. It is not always easy and yet every challenge of our lives is an opportunity to grow and to determine the way forward towards a better, healthier and more Joyful, Happy and Meaningful life. A life grounded in Service, to creating greater health for many and reducing dis-ease. While my focus is in helping woman this extends to men as well Watch here: https://youtu.be/MD-HLsV2GW4

In this episode during the month of January, we discuss this Transformational moment in history that we are all experiencing. It is not always easy and yet every challenge of our lives is an opportunity to grow and to determine the way forward towards a better, healthier and more Joyful, Happy and Meaningful life. A life grounded in Service, to creating greater health for many and reducing dis-ease. While my focus is in helping woman this extends to men as well Watch here: https://youtu.be/MD-HLsV2GW4

In this episode during the month of January, we discuss this Transformational moment in history that we are all experiencing. It is not always easy and yet every challenge of our lives is an opportunity to grow and to determine the way forward towards a better, healthier and more Joyful, Happy and Meaningful life. A life grounded in Service, to creating greater health for many and reducing dis-ease. While my focus is in helping woman this extends to men as well Watch here: https://youtu.be/MD-HLsV2GW4

Dr. Mitch Shulman joined Ken for his daily two minute checkup.

Targeted Treatments for Head and Neck Cancer with guest Dr. Barbara Burtness, December 15, 2024 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

On Call with the Prairie Doc® | Prairie Doc® host Dr. Andrew Ellsworth, with guests Dr. W. Chad Spanos from Avera Medical Group ENT-Head & Neck Surgery in Sioux Falls, SD and Dr. Kyle Armeson from Avera Medical Group Radiation Oncology in Sioux Falls, SD as they discuss head and neck cancer.

Advancements in treatment combined with a multimodal approach are improving outcomes for patients with head and neck cancer. However, the unique challenges of a head and neck cancer diagnosis and its treatment side effects—such as speech and communication difficulties as well as negative effects on body image and self-esteem—can significantly impact a patient's mental health. In this episode, CANCER BUZZ speaks with Jacquelyn Doenges, LCSW, MSSW, CTTS, clinical oncology social worker at UT Southwestern Medical Center—Harold C. Simmons Comprehensive Cancer Center, and Linda Hutkin-Slade, MSW, LCSW, OSW-C, clinical oncology social worker at David & Donna Long Cancer Center—Sharp Grossmont Hospital, about providing optimal psychosocial support for this patient population.  “Ask your patients ‘what is most valuable to you, what gets you up in the morning…what do you draw strength from?' If we can tap into what is essential for them to be happy in life, [we can] try to problem solve and build skills in them so that they can counter some of the issues that they'll experience because of their treatment.”–Jacquelyn Doenges, LCSW, MSSW, CTTS   “What we want is the patients at the center, and we want to build out a team around them so that they have as much support as possible, and that the energy is coming into the patient versus the patient trying to find these things [psychosocial care, dieticians, speech and language pathologists, oncology social workers].” –Linda Hutkin-Slade, MSW, LCSW, OSW-C   Guests:             Jacquelyn Doenges, LCSW, OSW-C, CTTS  Clinical Oncology Social Worker, Head and Neck Surgery  UT Southwestern Medical Center—Harold C. Simmons Comprehensive Cancer Center  Dallas, TX    Linda Hutkin-Slade, MSW, LCSW, OSW-C  Clinical Oncology Social Worker  David & Donna Long Cancer Center—Sharp Grossmont Hospital  San Diego, CA    This episode, developed in connection with the ACCC education program Multidisciplinary Approaches to Head and Neck Cancer Care, was made possible with support by EMD Serono.   Additional Reading/Sources Beyond the Brush: Navigating Dental Care in Head & Neck Cancer [Podcast] Ep 149 Making the Case for Head & Neck Cancer Patient Care Navigators [Podcast] Ep 143 Multidisciplinary Approaches to Head & Neck Cancer Care Head and Neck Patient and Caregiver Resources

People with cannabis use disorder are up to five times more likely to develop head and neck cancer than non-users. References: https://www.eurekalert.org/news-releases/1053923 https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2822269?guestAccessKey=6cb564cb-8718-452a-885f-f59caecbf92f&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=080824

Editor in Chief Cecelia E. Schmalbach, MD, MSc, is joined by author John Pang, MD, and Associate Editor Tristan Tham, MD, to discuss circulating tumor DNA (ctDNA) detection as a new technique to identify minimal residual disease in patients with solid tumors as outlined in the paper “ctDNA as an Adjunct to Posttreatment PET for Head and Neck Cancer Recurrence Risk Assessment” which published in the August 2024 issue of Otolaryngology–Head and Neck Surgery. They compare ctDNA to the traditional PET to assess best methods. Click here to read the full article.

This week Bobbi Conner talks with MUSC's Dr. Alexandra Kejner about the increasing use of transoral robotic surgery for head and neck cancer.

Did you know that dysphagia can occur not only in people with head and neck cancer, but also in people with cancers outside the anatomical swallowing regions? This is an area that is often overlooked in clinical practice and is also an under-researched topic. To shed light on this important issue, we interviewed Prof. Ciarán … EP 32: Dysphagia beyond head and neck cancer with Ciarán Kenny Read More »

Dr. Sid Puram, clinical oncologist at Siteman Cancer Center and Tom Ackerman discuss prevention and treatment of head and neck cancers.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NQB865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.Progress Meets Innovation in Head and Neck Cancer: Perspectives on Modern Immunotherapy and Novel Therapeutic Mechanisms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Head and Neck Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from AVEO Pharmaceuticals, Inc., Coherus BioSciences, Inc., and Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NQB865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.Progress Meets Innovation in Head and Neck Cancer: Perspectives on Modern Immunotherapy and Novel Therapeutic Mechanisms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Head and Neck Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from AVEO Pharmaceuticals, Inc., Coherus BioSciences, Inc., and Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NQB865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.Progress Meets Innovation in Head and Neck Cancer: Perspectives on Modern Immunotherapy and Novel Therapeutic Mechanisms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Head and Neck Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from AVEO Pharmaceuticals, Inc., Coherus BioSciences, Inc., and Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NQB865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.Progress Meets Innovation in Head and Neck Cancer: Perspectives on Modern Immunotherapy and Novel Therapeutic Mechanisms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Head and Neck Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from AVEO Pharmaceuticals, Inc., Coherus BioSciences, Inc., and Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NQB865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.Progress Meets Innovation in Head and Neck Cancer: Perspectives on Modern Immunotherapy and Novel Therapeutic Mechanisms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Head and Neck Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from AVEO Pharmaceuticals, Inc., Coherus BioSciences, Inc., and Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NQB865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.Progress Meets Innovation in Head and Neck Cancer: Perspectives on Modern Immunotherapy and Novel Therapeutic Mechanisms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Head and Neck Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from AVEO Pharmaceuticals, Inc., Coherus BioSciences, Inc., and Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor sat down with Erica Fortune, PhD, Vice President of Research at Cancer Support Community, to discuss her team's poster entitled, “Head and Neck Cancer (HNC) Survivors: Long-Term Nutrition Impact Symptoms, Eating Problems, and Barriers to Care Impact Psychosocial Health.” In this podcast, Dr. Fortune delves further into this topic, including: Background about long-term side effects and quality-of-life impacts experienced by HNC survivors Cancer Support Community's survey designed to further investigate these challenges The results that the study found regarding nutrition, eating problems, and barriers to care that survivors experience How Cancer Support Community plans on using the survey results to improve survivorship and address psychosocial impacts experienced by long-term HNC survivors A preview of other topics that Cancer Support Community is excited to cover as a member organization of the Oncology Data Advisor Editorial Board And more!

Dr Hisham Mehanna (University of Birmingham, Birmingham, UK) and Dr Sue Yom (University of California, San Francisco, San Francisco, CA, USA) discuss their four-paper Series on Head and Neck Cancer Consensus Recommendations in diagnosis and clinical trial endpoints.Tell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!

Our coverage of ASCO 2024 has rounded the final bend, and the finish line is in sight. Today, Josh and Michael examine four studies in the head and neck cancer space. Today's studies include a novel, viral-driven vector that aims to increase the immune response to treatment, potential treatment for the very rare nasal squamous cell cancer, data supporting the treatment of patients with poor prognosis and head and neck patients, and a new, intensive immunotherapy treatment for nasopharyngeal cancer. A wide variety of studies that are sure to satisfy a broad range of palates!Links to studies discussed in this episode (subscription may be required):TARGET-HPV: LinkPhase 3 randomized study for evaluation of physician choice Rx versus best supportive care as second-line or beyond therapy in head and neck cancer with poor performance status: LinkKCSG HN18-07: LinkTislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial: LinkFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comOncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.Art courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

Featuring perspectives from Ms Meetal Dharia, Dr Robert L Ferris, Dr Robert Haddad and Ms Lynsey P Teulings, including the following topics: Introduction (0:00) The Biology of Head and Neck Cancer (15:41) The Multidisciplinary Treatment of Head and Neck Cancer (18:14) Ongoing Screening and Prevention After Potentially Curative Therapy for Head and Neck Cancer (33:03) Radiation Therapy and Chemotherapy Side Effects (41:02) The Potential Short- and Long-Term Effects of Surgery for Head and Neck Cancer (49:50) Emerging Treatment Strategies Aimed at Improving Outcomes Associated with Localized or Locally Advanced Head and Neck Cancer (56:46) Tolerability Considerations with Xevinapant (1:06:13) The Established Role of Anti-PD-1/PD-L1 Antibodies in Therapy for Advanced Head and Neck Cancer (1:17:35) Newly Approved Immunotherapeutic Strategies for Nasopharyngeal Carcinoma (1:19:27) The Tolerability of Immune Checkpoint Inhibitors (1:24:09) NCPD information and select publications

It was about time we had a conversation about dysphagia in people with head and neck cancer (HNC). And this time our guest was none other than Prof Katherine A Hutcheson from the University of Texas, MD Anderson Cancer Center. Kate answered all our questions about HNC-related dysphagia and its presentation, prehabilitation and instrumental assessment … EP 31: Dysphagia in head and neck cancer with Kate Hutcheson Read More »

In this episode of 'Navigating Cancer TOGETHER,' host Talaya Dendy interviews Heather Noggle, a 33-year cancer thriver and the owner of Codistac, a process solutions company that weaves technology and human experience together to guide customers to find unique answers to their most vexing problems. They discuss Heather's experience with parotid salivary gland cancer, the emotional and mental challenges post-diagnosis, and the significance of resilience. Heather shares her journey of adapting to life after cancer, the importance of a support system, and her professional career in cybersecurity. This episode emphasizes hope and resilience, encouraging listeners to find normalcy and joy after cancer.✨Highlights from the show:[01:26] Introducing Heather Noogle: A 33-Year Cancer Thriver's Journey[04:41] Understanding Salivary Gland Cancer [06:17] The Impact of Cancer Diagnosis at a Young Age[07:42] Navigating Cancer Treatment and Its Aftermath[20:14] Heather's Life and Career Post-Cancer[24:19] Embracing Resilience: Heather's Key to Surviving Cancer[28:14] Closing Thoughts and Inviting Audience Reflection

If you want to serve the head and neck cancer population or HOPE to one day…you do NOT want to miss this episode! Jennifer Larssen, an SLP at the University of South Florida, shares her experiences in developing innovative programs for head and neck surgery patients. She shares innovative programs and tools like… ✅A groundbreaking laryngeal speaking device for those who struggle with the traditional electrolarynx. ✅A self-dilation program for patients with laryngectomy and/or radiation to the neck. ✅A TEP clinic. ✅Support groups - include one for women who have undergone a laryngectomy. ✅Social events (like a trip to Busch Gardens and makeup lessons post-surgery and/or radiation) Prepare to feel inspired! Download the show notes: https://syppodcast.com/330 TIMESTAMPS:   Introduction (00:00:00) Program Development at USF (00:00:42) Tracheoesophageal Prostheses and TEP Clinics (00:02:51) Larynx Demo Days (00:03:09) Competencies in TEP Changes (00:04:28) Self-Dilation Program (00:06:13) Advocating to Administration (00:07:56) Head and Neck Cancer Community Group (00:09:26) Funding and Resources (00:12:21) Women's Retreat (00:13:06) Clinical Pathway and Rehabilitation (00:16:38) Feeding Tube Removal (00:19:32) Collaboration with Dietitian (00:20:11) Patient Observation (00:20:54) Transitional Care Program (00:21:44) Fluoro MS Suite (00:23:33) Becoming an X-Ray Tech (00:25:09) Supportive Team at USF (00:28:11) Human Element in Healthcare (00:30:43) The post 330 – Makeup Lessons, TEP Clinics, Self-Dilation Programs, and More: Innovative Services for the Head and Neck Cancer Population appeared first on Swallow Your Pride Podcast.

Could clinical hypnosis improve outcomes for patients? Find out with Sarah Partridge, Consultant in Clinical Oncology at Imperial Healthcare NHS Trust, London. In this episode, Jonathan and Partridge discuss how hypnosis can be harnessed in a clinical setting, how it can be normalised, and its impact managing side effects. Use the following timestamps to navigate our episode! (00:00)-Introduction (01:45)-Sarah's route to clinical oncology (04:22)-Discovering and implementing hypnosis as a tool (08:12)-Hypnosis in managing side effects (12:18)-Hypnosis in clinical scenarios (16:31)-Tranceform: The era of digital resources (21:00)-Normalising clinical hypnosis (24:51)-Hypnosis: A different form of dissociative state

Dr. Douglas Peterson presents the latest evidence-based guideline from ISOO, MASCC, and ASCO on the prevention and management of osteoradionecrosis (ORN) in patients with head and neck cancer treated with radiation therapy. He covers topics such as recommended initial workup, best practices for prevention of ORN of the head and neck before and after radiation therapy, nonsurgical and surgical management of ORN, and management of adverse events associated with ORN. Dr. Peterson also comments on the importance of this guideline and what researchers should address moving forward. Read the full guideline, “Prevention and Management of Osteoradionecrosis in Patients with Head and Neck Cancer Treated with Radiation Therapy: ISOO-MASCC-ASCO Guideline” at www.asco.org/head-neck-cancer-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/head-neck-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO.23.02750.   Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts, bringing you timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all our shows, including this one, at asco.org/podcasts.   My name is Brittany Harvey and today, I'm interviewing Dr. Douglas Peterson from UConn Health, lead author on “Prevention and Management of Osteoradionecrosis in Patients with Head and Neck Cancer Treated with Radiation Therapy: International Society of Oral Oncology, Multinational Association for Supportive Care in Cancer, American Society of Clinical Oncology Guideline.” Thank you for being here, Dr. Peterson. Dr. Douglas Peterson: Thank you, Brittany. My pleasure to be here. Brittany Harvey: Before we discuss the guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensures that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Peterson, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes.  So then, to dive into the topic we're here to discuss, Dr. Peterson, could you first provide an overview of the scope and purpose of this joint ISOO-MASCC-ASCO guideline? Dr. Douglas Peterson: I'll be pleased to do so, Brittany. Again, thank you for the opportunity to represent the panel in this guideline. The panel has strived to present a guideline that brings consistency in clinical practice regarding prevention and management of osteoradionecrosis of the jaw (ORN) based on the highest quality contemporary science. Given the mechanistic and clinical complexity of ORN, we also stress the importance of interprofessional oncology care of these patients. The team includes, but is not limited to, clinicians representing radiation oncology, head and neck surgery, medical oncology, otolaryngology, dental medicine, oral medicine, oral oncology, oral and maxillofacial surgery, and patient advocacy organizations. So it really is a collective enterprise that we bring to bear in the guideline.  In some cases, the panel has been fortunate to be able to utilize a high quality evidence base in the literature upon which we could build strong recommendations. In selected other cases, however, we utilized informal consensus given the low evidence quality in the field. The recommendations presented have been carefully framed in this context, with the goal of providing state-of-the-science guidelines in clinical decision making and management of ORN. I'd also like to point out that the guideline brings linkage to other guidelines published by ASCO and other major oncology organizations, regarding management of symptoms and other supportive care needs associated with ORN. These companion guidelines include addressing pain, dysphagia, oral care, trismus, and psychosocial impact and survivorship, to name a few. I'd also like to say that combining the expertise of ISOO, MASCC, and ASCO has provided an important opportunity to produce this guideline. This has been a comprehensive effort by many experts. In addition to the outstanding input from the panel, I am also personally so very grateful for the expert input from ASCO's Evidence-Based Medicine Committee, as well as endorsements from other key organizations, including the American Head and Neck Society, the American Society for Radiation Oncology, and the American Academy of Oral Medicine as endorsees of the guideline. Finally in addition, Dr. Nofisat Ismaila's leadership as ASCO staff has been absolutely invaluable as well.  Brittany Harvey: Excellent. I appreciate you providing that background on the development of this evidence-based guideline, which was developed by a multi-organizational and multidisciplinary panel.   So to dive into the key recommendations of this guideline, this guideline addresses six clinical questions. So, starting with question one, what key points would you like to highlight regarding how ORN is characterized, graded, and reported, and what is the recommended initial workup for patients?  Dr. Douglas Peterson: Osteoradionecrosis of the jaw of the mandible and maxilla should be characterized in the view of the panel as a radiographic, lytic, or mixed sclerotic lesion of bone, and/or visibly exposed bone, and/or, importantly, bone probed through a periodontal pocket or fistula. In the latter case, the clinical appearance of exposed bone may be extremely subtle. ORN is occurring within an anatomical site previously exposed to a therapeutic dose of head and neck radiation therapy. So we have a combined radiographic/clinical approach characterizing the lesion in the context of the patient having received previously a therapeutic dose of head/neck radiation therapy. We do recommend that clinicians evaluate ORN based on the most contemporary staging system, the ClinRad system, which is cited in the publication itself. We also advocate for the use of the ClinRad staging system not only in clinical assessment of patients, but also in clinical trials moving forward. We'll touch a little bit later on future research opportunities as well.  Finally, the initial evaluation of ORN should include a clinical intraoral examination, and again, the appearance of exposed bone may be extremely subtle, and/or a formal radiographic examination. The guideline delineates the various types of radiographic examinations that we recommend.  Brittany Harvey: Understood. Thank you for reviewing those recommendations regarding reporting and characterization of ORN, as well as the workup.   The next section of the guideline, it focuses on best practices to prevent ORN of the head and neck prior to radiation therapy. What are the key recommendations of that section?  Dr. Douglas Peterson: As with other adverse events in oncology patients, prevention is key. Prevention of ORN does require interprofessional management. The guideline lists several key recommendations along these lines. Now, an important caveat in what the guideline presents is that the target coverage of the tumor should not be compromised in order to avoid radiation dose to bone. So that's a very important caveat. Now having said that, focused effort should be made to reduce the mean dose to the jaw and the volume of bone receiving above 50 Gy whenever possible. So it's really a balance between maximizing target coverage of the tumor while limiting exposure to normal bone. In addition, a dental assessment by a dentist and dental specialist, if possible, is strongly advised prior to therapeutic-intent radiation therapy. The purpose of this assessment by the dental team is to identify and remove teeth which will place the patient at risk of developing ORN during the patient's lifetime, and to comprehensively educate the patient about the lifelong risk of ORN. Dental extraction in advance of radiation is often a consideration to these patients, and if clinically indicated, should occur at least two weeks prior to the commencement of radiation therapy. Now having said that, in the setting of a rapidly progressive tumor, extraction should be deferred and not cause delay in the initiation of radiation therapy. Brittany Harvey: So you just touched on key points of prevention prior to radiation therapy. Following those recommendations, what does the expert panel recommend regarding best practices to prevent ORN after radiation therapy? Dr. Douglas Peterson: This can be a challenging clinical issue. So the panel recommends that before finalizing dental treatment plans that may include extractions in patients with a history of head and neck radiation therapy, a review of the radiation therapy plan should be performed with particular attention focused on dose to the mandible and maxilla. For teeth in areas of high-risk for ORN, alternatives to dental extraction may be possible, for example, root canal or endodontic procedures, crowns, or dental restorations, or dental filling should be offered unless the patient has recurrent infections, intractable pain, or other symptoms that cannot be alleviated without extraction. So it really becomes a combined clinical decision making effort between the dental team and oncology team.  One controversial area has been hyperbaric oxygen being administered prior to dental extractions in patients who have received head and neck radiation therapy previously. The panel does not recommend routine use of prophylactic HBO prior to dental extractions in these patients who have received prior head and neck radiation therapy. However, the evidence base here is limited with low quality and we offer a weak strength of recommendation. It is a controversial area, so we did also include a qualifying statement that prophylactic HBO may be offered to patients undergoing invasive dental procedures at oral sites where a substantial volume of the mandible and/or maxilla receive at least 50 Gy. This is an area of controversy. We can talk about this in the future research directions, but clearly, new high quality research related to the role of HBO in the management of these patients is needed.  Brittany Harvey: Definitely. Thank you for touching on those points and that area of controversy. We can definitely touch on that a bit later as we talk about future research in this field.  As you mentioned, Dr. Peterson, this guideline addresses both prevention and management. So, in moving into the management of ORN, how should ORN be managed nonsurgically?  Dr. Douglas Peterson: The guideline relative to nonsurgical management of ORN is focused on the use of pentoxifylline. Now this maybe used in, and this is important, in cancer-free patients with mild, moderate, and severe cases of ORN. But pentoxifylline, the guideline also notes, is most likely to have a beneficial effect if the treatment is combined with tocopherol, antibiotics, and prednisolone as well. So there's clinical judgment involved in the nonsurgical management of ORN, centered with pentoxifylline in combination with tocopherol, antibiotics, and prednisolone. Brittany Harvey: Understood. And then expanding on the management of ORN, what are the key points for surgical management of ORN? Dr. Douglas Peterson: The panel offered several recommendations for which the strength of the recommendations was strong. Just to cite a few, in partial thickness ORN as defined by the ClinRad stage one and two that we talked about earlier, surgical management can start with transoral minor interventions which can lead to resolution over time. It may take time. It may take weeks or even a few months. Now this minimally invasive surgery may include debridement, sequestrectomy, alveolectomy, and/or soft tissue flap closure. Furthermore, small defects, clinically, for example, less than 2.5 cm in length, may heal spontaneously with local topical measures such as we described. It is recommended that larger defects, larger than 2.5 cm, in general be covered with vascularized tissue.  Brittany Harvey: Appreciate you reviewing those recommendations regarding surgical management of ORN. So to wrap up our discussion of the recommendations with the final clinical question, what is recommended for assessment and management of adverse events associated with ORN?  Dr. Douglas Peterson: This is a really important area as well in addition to prevention and management of ORN per se. The panel recommends that patients should be assessed by their healthcare providers for the presence of adverse events at the time of ORN diagnosis and periodically thereafter until the adverse event resolves based on patient status including any interventions or the adverse events that are clinically indicated. The panel and its literature evaluation learned that there is a relative lack of data specifically directed to the management of adverse events associated with ORN. However, this is such an important area that we wanted to address it head on. And so the management we recommend should be informed by pertinent available other guidelines that had been developed for analogous symptoms and/or disease states. The guideline provides links to these companion guidelines developed by ASCO as well as by MASCC and ISOO, the European Society of Medical Oncology, and NCCN. And so in the guideline we provide links on management of adverse events as produced by these other organizations. Table 3 presents a summary of the guidelines that address symptoms and supportive care needs associated with ORN.  Brittany Harvey: Thank you for reviewing all of these recommendations. It's clear that the panel put a lot of work and thought into these recommendations and provided needed guidance in areas with limited evidence. We'll have links available in the show notes for listeners to be able to go and read these recommendations for themselves and refer to the tables that you mentioned.  So in your view, Dr. Peterson, what is the importance of this guideline and how will it impact clinicians and patients with head and neck cancer? Dr. Douglas Peterson: As we talked about throughout this podcast, the guideline is designed to synthesize the contemporary science regarding ORN and translate that into recommendations for clinical practice in both prevention and management. As noted in the guideline, oncologists plus other interprofessional healthcare providers have been directly involved in the creation of the guideline, that interprofessional theme, which we believe is so essential given the mechanistic and clinical complexity of ORN.  Now, in addition to the expertise of the panel, the pending widespread distribution of the guideline represents an additional important opportunity for extending the impact across clinical oncology. So in addition to the publication in the Journal of Clinical Oncology, dissemination by MASCC and ISOO as well as our endorsees, the American Head and Neck Society, the American Society for Radiation Oncology, and the American Academy of Oral Medicine will also be key in broadening the impact and hopefully the utilization of the guideline. And members of these organizations may very well be involved in the management of these patients as well.  And then finally, the guideline is also designed to stimulate future research based on current gaps of the knowledge and we touched on some of those gaps, for example, with HBO for which new high quality research is needed.   Brittany Harvey: Absolutely. It's great to have so many partners in this guideline and we hope that this guideline will have a large impact for patients with head and neck cancer to improve their quality of life.   So then your final comment leads nicely into my last question and that we've already talked a little bit about some of the future research opportunities that this guideline highlights. So, to wrap us up, Dr. Peterson, what are the outstanding questions regarding osteoradionecrosis of the jaw secondary to head and neck radiation therapy in patients with cancer?  Dr. Douglas Peterson: There are several key areas that the panel identified as we went through a rigorous review of the highest quality literature. Some of the key areas to address moving forward include: prospective studies are needed to evaluate the clinical presentation, trajectory, and response to treatment of ORN-related symptoms and function impairment, in other words, the adverse event side of the story. In addition, social determinants of health, quality of life, and psychosocial impact of ORN warrant further investigation in head and neck cancer survivors as well. In addition, new research including randomized controlled trials and prospective multicenter trials regarding the systemic and surgical treatment of ORN is also warranted, and we touched on, for example, hyperbaric oxygen. Hyperbaric oxygen has been a long standing management strategy of ORN. However, the trials to date are of limited quality in relation to supporting its use. So high quality new research related to the role of HBO in these patients is needed.   And the expert panel also encourages creation of predictive tools, a priori tools, directed to development, grading, and staging of ORN. These could include, for example, bone turnover markers and genetic markers to name two. And finally, the research opportunities that are presented in the guidelines such as what I briefly summarized today should ideally be addressed in large prospective multicenter observational studies of risk, outcomes, and financial cost of ORN or the various treatment strategies that are highlighted in the guideline.    Brittany Harvey: Excellent. Well, we'll look forward to research that addresses those outstanding questions and I want to thank you so much for your all your work on this guideline and for taking the time to share the highlights of this guideline with me today, Dr. Peterson.  Dr. Douglas Peterson: Thank you. My privilege to do so, Brittany. Brittany Harvey: And thank you to all our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/head-neck-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app in the Apple App Store or the Google Play Store. If you have enjoyed what you heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Interview with Evan M. Graboyes, MD, MPH, author of Neighborhood-Level Disadvantage and Delayed Adjuvant Therapy in Head and Neck Cancer. Hosted by Paul C. Bryson, MD, MBA. Related Content: Neighborhood-Level Disadvantage and Delayed Adjuvant Therapy in Head and Neck Cancer

In celebration of Head and Neck Cancer Awareness Month this April, Oncology Data Advisor Fellows Forum and Editorial Board Members Samuel Kareff, MD, MPH; Matthew Hadfield, DO; and Nagashree Seetharamu, MD, sat down to discuss the epidemiology of head and neck squamous cell carcinomas (HNSCC), the diagnostic and treatment process of HNSCC, including: –Epidemiologic trends –Geographic distribution –Approved screening methods –Novel treatment combinations –Side effects and adverse events –Survivorship –And more!

Head and neck cancers have always been some of the most difficult to treat, but advancements in robotic surgery, advanced imaging, and multidisciplinary recovery approaches are improving the outlook for many patients. Benjamin Greene, M.D.; Harishanker Jeyarajan, M.D.; and Carissa Thomas, M.D., share new insights and techniques in the field. Learn more about the connection between HPV and oropharyngeal cancer; new tools allowing more accurate diagnoses and monitoring for recurrence; and the surgical precision made possible by robotic surgery alongside intraoperative fluorescence imaging.

Breakthrough Radiotherapy Provides New Options for Patients with guest Zafar Syed April 7, 2024

Guest: Fred Stal, MS CCC-SLP, CBIS - Head and neck cancer patients face unique challenges in their assessment and treatment journey. Late effects of radiation and lymphedema can further complicate their recovery. This episode will explore the assessment, treatment, and impact of late effects on these patients. Let's explore the complexities and strategies to navigate these issues effectively. Join Renee and Fred for this hour of research-based clinical practice and the role of the SLP with this population.

Do you know the optimal management of your patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN)?    Credit available for this activity expires: 3/18/2025 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000404?ecd=bdc_podcast_libsyn_mscpedu

There's a virus that infects just about every adult. It's passed by skin-to-skin contact – most often during sexual intercourse. It's the human papillomavirus (HPV for short). It often doesn't show any symptoms, and at times the infection resolves on its own.  It can cause warts, but more ominously, HPV is the single biggest cause of cervical cancer. It's also a factor in common cancers of the head and neck, as well as cancers of the anus and penis. It's the main reason most adult women must undergo regular Pap smears, which work well to catch the changes that can lead to cancer while still treatable. But there's no Pap smear for the mouth and throat, and none for the anus or penis either.  So the invention of a vaccine that prevents cancers caused by HPV should have people running to get it. It has been proven very safe and effective. According to the US Centers for Disease Control and Prevention, infections with the strains of HPV that cause cancers and genital warts have dropped 88 percent in vaccinated teen girls, and 81 percent among vaccinated young women.While vaccination has focused on girls, boys and men suffer from and spread this infection. A study in the Lancet Global Health found nearly a third of men and boys over the age of 15 are infected with at least one genital strain of HPV and one in five have a cancer-causing type.Studies show that the earlier teens get the vaccine against HPV, the better it protects them. But people are resisting it. Dr. Grace Ryan, assistant professor of population & quantitative health sciences at the University of Massachusetts Chan Medical School, is looking at why people are hesitant to use this life-saving vaccine, and at how to get people to better understand its benefits.In this episode of One World, One Health, Dr. Ryan chats with host Maggie Fox about what she's found about HPV vaccine hesitancy.

Editor-in-Chief Sue Yom hosts Dr. Lachlan McDowell, a consultant Radiation Oncologist at the Princess Alexandra Hospital and the first author of a new paper this month, "A longitudinal study evaluating sexual health outcomes and prioritization in patients undergoing chemoradiation for human papillomavirus-associated oropharyngeal cancer," Dr. Jie Deng, Professor of Nursing, Senior Fellow at the Leonard Davis Institute of Health Economics, and Faculty Director of the Laboratory of Innovative & Translational Nursing Research at the University of Pennsylvania, and Dr. Barbara Murphy, Professor of Medicine, Hematology and Oncology Division Director, and Director of the Pain and Symptom Management Oncology Services at Vanderbilt University. Drs. Deng and Murphy were the first and last authors on a second paper this month, Longitudinal Pattern of Lymphedema and Fibrosis in Patients with Oral Cavity or Oropharyngeal Cancer: A Prospective Study.

From educating restaurant staff to bringing recipes to support groups, it's important to humanize dysphagia care.  And when it comes to fostering that approach with the head and neck cancer population, Theresa Yao, SLPD, MEd, MS, CCC-SLP will be the first to speak up! Tune into this week's episode of the Swallow Your Pride Podcast podcast to explore a holistic approach to managing dysphagia. Going beyond the bedside, Theresa shares the importance of considering personal factors, environment, and social participation alongside the swallowing impairment itself.  What does it mean to create a dysphagia-friendly community? How can you advocate for it? What extra steps can you take to help your patients with head and neck cancer - or dysphagia in general - feel more empowered?  Grab your notepad and prepare to get inspired. You won't want to miss this! Get the show notes for this episode here: https://syppodcast.com/313 Timestamps: Theresa Yao's background (00:01:21) The journey to voice and swallowing disorders (00:02:05) The importance of a whole-person approach (00:05:51) The whole person approach to dysphagia (00:06:51) Viewing patients as whole persons (00:08:51) The impact of dysphagia on social interactions (00:10:13) Involving patients in treatment planning (00:12:14) Creating dysphagia-friendly environments (00:15:58) The role of support groups in dysphagia management (00:17:55) The support group and patient empowerment (00:18:44) Support group advocacy and volunteer efforts (00:20:50) Community outreach and resources (00:21:57) Benefits of support groups for clinicians (00:25:14) Community engagement and awareness (00:27:06) Multidisciplinary team approach (00:28:28) Patient-reported outcome measures and quality of life assessment (00:30:44) Whole person approach and qualitative research (00:33:29) The post 313 – The Human Behind the Dysphagia: A Holistic Approach for Head and Neck Cancer Patients appeared first on Swallow Your Pride Podcast.

Understanding the progression of a cancerous head and neck tumor, “how it started and how it evaded the immune system and got into the blood stream and spread provides a wealth of information we can utilize and gives us more treatment options,” said James Rocco, a head and neck cancer specialist and chair of the James Cancer Hospital's Head and Neck Surgery Department. In this episode, Rocco discusses how he and his collaborators have developed a computational data analytics program called PhylogicNDT. The program will evaluate the progression of head and neck cancer tumors caused by the human papillomavirus (HPV) and they believe “this approach can be applied to other types of cancers,” Rocco said. Diagnosing head and neck tumors in the early stages, when the tumor mutations are less complex and easier to treat, can be problematic. This is because the symptoms don't usually appear until the tumor has progressed significantly. However, “looking at the circulating DNA in someone's blood can detect head and neck cancer in the earliest stages,” Rocco said of this type of blood analysis. “We're not there yet with circulating DNA but we're getting close.”